Company Website:
http://www.sanofigenzyme.com
CAMBRIDGE, Mass. -- (Business Wire)
Sanofi
Genzyme, the specialty care global business unit of Sanofi,
announced today a research collaboration with the Johns Hopkins School
of Medicine that will focus on novel strategies aimed at advancing the
understanding of underlying causes of disease progression in multiple
sclerosis (MS). The collaboration, under guidance by a joint committee
of representatives from Sanofi Genzyme and the Johns Hopkins Multiple
Sclerosis Center, will leverage certain technologies and methodologies
designed to inform new therapeutic approaches to treating disease
progression.
As one of the largest clinical and research MS centers globally, the
Johns Hopkins Multiple Sclerosis Center brings a breadth of expertise
and an established foundation of novel research approaches that
complement Sanofi Genzyme’s MS research priorities.
“While there are currently no approved treatments for progressive
forms of MS, the research landscape is evolving to where we are learning
more about the underlying biology of disease progression,” said
Michael Panzara, MD, Head of MS, Neurology and Ophthalmology Therapeutic
Area, Global Development, Sanofi Genzyme. “Collaborations like this
are important to advancing interventional strategies that slow
relentless progression in MS. We are excited about the potential of this
collaboration to advance our understanding of disease progression,
enabling more rapid development of the next generation of MS therapies.”
Sanofi Genzyme’s MS research pipeline includes collaborations with
academic medical centers that explore the pathogenesis of MS and
potential novel therapeutics. Initiatives include identifying biomarkers
of disease progression and exploring strategies to address
neurodegeneration, considered to be a key factor driving disability
accumulation in MS.
About Sanofi
Sanofi, a global healthcare leader, discovers,
develops and distributes therapeutic solutions focused on patients'
needs. Sanofi is organized into five global business units: Diabetes and
Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme,
Sanofi Pasteur and Merial. Sanofi is listed in Paris (EURONEXT: SAN) and
in New York (NYSE: SNY).
Sanofi Genzyme focuses on developing specialty treatments for
debilitating diseases that are often difficult to diagnose and treat,
providing hope to patients and their families. Learn more at www.sanofigenzyme.com.
Genzyme® is a registered trademark of Genzyme Corporation.
Sanofi® is a registered trademark of Sanofi. All rights
reserved.
Sanofi Forward-Looking Statements
This press
release contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts. These
statements include projections and estimates and their underlying
assumptions, statements regarding plans, objectives, intentions and
expectations with respect to future financial results, events,
operations, services, product development and potential, and statements
regarding future performance. Forward-looking statements are generally
identified by the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various risks
and uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These
risks and uncertainties include among other things, the uncertainties
inherent in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such as
the FDA or the EMA, regarding whether and when to approve any drug,
device or biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential of
such product candidates, the absence of guarantee that the product
candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group’s
ability to benefit from external growth opportunities, trends in
exchange rates and prevailing interest rates, the impact of cost
containment initiatives and subsequent changes thereto, the average
number of shares outstanding as well as those discussed or identified in
the public filings with the SEC and the AMF made by Sanofi, including
those listed under “Risk Factors” and “Cautionary Statement Regarding
Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for
the year ended December 31, 2015. Other than as required by applicable
law, Sanofi does not undertake any obligation to update or revise any
forward-looking information or statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160516005953/en/
Contacts:
Sanofi Genzyme
Media Relations
Erin Walsh, +1-617-768-6881
Erin.Walsh@genzyme.com
Source: Sanofi Genzyme
© 2024 Canjex Publishing Ltd. All rights reserved.